> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Hetero Drugs FDA-483
- URL: https://www.fdaweb.com/hetero-drugs-fda-483/
- Published: 2018-07-19T12:00:00.000Z
- Updated: 2026-09-15T00:20:34.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141916

FDA has released the FDA-483 issued following a 2/26-3/2 inspection at Hetero Drugs, a Sangareddy District, India, active pharmaceutical ingredient producer. The [form](https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/CDERFOIAElectronicReadingRoom/UCM613741.pdf?ref=fdaweb.com) says specific inspection observations were: 

- failing to thoroughly review any unexplained discrepancy and failure of a batch or any of its components to meet any of its specifications, whether or not the batch has been already distributed;
- failing to fully follow responsibilities and procedures applicable to the quality control unit;
- employees engaged in the processing, holding, and testing of a drug product lack the training and experience required to perform their assigned functions;
- there is no assurance that equipment used in the production of a specific active pharmaceutical ingredient are always maintained and/or kept in proper conditions for manufacturing operations and to prevent the contamination of the products handled and/or processed by the equipment; and
- separate or defined areas to prevent contamination or mix-ups are deficient regarding laboratory controls and operations.